2Lenz HJ. Management and preparedness for infusion and hypersensi- tivity reactions[ J]. Oncologist, 2007,12:601-609.
3O' Nell BH, Alien R, Spigel DR, et al. High incidence of cetnx- imab-related infusion reactions in Tennessee and North Carolina and the association with atopic history[J]. J Clin 0ncol,2007,25:3644- 3648.
4Cerman J, Melichar B, Cermanova M, et al. Management of severe infusion reactions after cetuximab [ J ]. Acta Oncol, 2008,47 ( 8 ) : 1609-1611.
5Schwartzberg LS, Stepanski E J, Fortner BV, et al. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: Assessment of clinical consequences [ J ]. Support Care Cancer, 2008,16 : 393-398.
二级参考文献25
1Enomoto M, Ochi M, Teramae K, et al. Codeine phosphate-induced hypersensitivity syndrome. Ann Pharmacother, 2004, 38: 799-802.
2Mitani N, Aihara M, Yamakawa Y, et al. Drug-induced hypersensitivity syndrome due to cyanamide associated with multiple reactivation of human herpesviruses. J Med Virol, 2005, 75: 430-434.
3Tohyama M, Yahata Y, Yasukawa M, et al. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol, 1998, 134:1113-1117.
4Suzuki Y, Inagi R, Aono T, et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol, 1998, 134:1108-1112.
5Aihara Y, Ito SI, Kobayashi Y, et al. Carbamazepine-induced hypersensitivity syndrome associated with transient hypogammaglobulinaemia and reactivation of human herpesvirus 6 infection demonstrated by real-time quantitative polymerase chain reaction. Br J Dermatol, 2003, 149: 165-169.
6Hashimoto K, Yasukawa M, Tohyama M. Human herpesvirus 6 and drug allergy. Curt Opin Allergy Clin Immunol, 2003, 3: 255-260.
7Kano Y, Inaoka M, Sakuma K, et al. Virus reactivation and intravenous immunoglobulin ( IVIG ) therapy of drug-induced hypersensitivity syndrome. Toxicology, 2005, 209: 165-167.
8Ohtani T, Hiroi A, Sakurane M, et al. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyfidine. Br J Dermatol, 2003, 148: 1035-1039.
9Martin AM, Nolan D, Gaudieri S, et al. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics, 2004, 5: 643-655.
10Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002, 359:727-732.
